Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D.
|
|
- Camilla Debra Daniel
- 6 years ago
- Views:
Transcription
1 Role of Innate Immunity in Hepatitis B Virus Infection Adam J. Gehring, Ph.D. Biology Lead Toronto Centre for Liver Disease Toronto General Hospital Research Institute University Health Network (UHN)
2 HBV Recognition by Innate Immunity CD14/TLR-4 Historically, HBV seen as a stealth virus Not visible to innate sensing mdc CD14 Mounting evidence for HBV recognition Multiple pattern recognition receptors TLR-2 CD14/TLR-4 RIG-I cgas Cooper, J. Immunol. 175, (2005). Vanlandschoot, J. Gen. Virol (2002). van Montfoort, J. Virol. JVI (2016). Sato. Immunity 42, (2014). Cui. J. Virol. 90, (2015).
3 HBV Recognition by Innate Immunity CD14/TLR-4 mdc CD14 Recognition inflammation Evidence HBV can inhibit signaling HBV polymerase, X Caveat Transfection systems Stimuli was not HBV Restricted to hepatocytes PBMC not infected Infection systems may clarify Cooper, J. Immunol. 175, (2005). Vanlandschoot, J. Gen. Virol (2002). van Montfoort, J. Virol. JVI (2016). Sato. Immunity 42, (2014). Cui. J. Virol. 90, (2015).
4 Innate Immune Response in Chronic HBV Vertical transmission accounts for a majority of chronically infected patients Innate immune system is exposed to HBV before birth No longer any acute response to HBV because virus is always present Hong. Nat Comms 6, 1 12 (2015).
5 Innate Immune Response in Chronic HBV Innate immune system displays a regulatory role during chronic HBV infection Suppress anti-hbv immunity Regulate inflammation Innate immune cells dominate the immune composition of the liver
6 Innate Immune Regulation in Chronic HBV Myeloid-derived suppressor cells (MDSC) Expanded in chronic HBV patients IL-10 & arginase suppress T cells Kupffer cells produce IL-10 in response to HBV core antigen Mouse model Suppression of T cell immunity T cell NK cell TRAIL expression HBV-specific T cells express increased receptor for TRAIL NK-mediated depletion of HBV-specific T cells Pallett. Nat Med 21, (2015). Li. J. Immunol. 195, (2015). Peppa J. Exp Med. 210, (2013).
7 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).
8 Blocking NK TRAIL-mediated killing of HBVspecific T cells. NK X TRAIL T Peppa J. Exp Med. 210, (2013).
9 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).
10 Inducing presentation of the HBV antigen depot in monocytes CD14 MN GM-CSF + IL-4 6d Co-culture +/- Activation Monocyte-derived DC HBsAg-specific CD8 T cell 8/9 Healthy Chronic HBV HLA-mismatched A0201 Cw0801 Chronic HBV HLA-matched Gehring et al, J Clin Invest. 2013;123(9):
11 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).
12 TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 TLR-8 NK & MAIT IL-12/18 IFN-γ NK bright MAIT IFN-γ TNF-α Jo et. al. PLoS Pathog Jun;10(6):e
13 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).
14 TLR-7 mediated IFN-alpha production from plasmacytoid DC. GS-9620 TLR-7 IFN-α ISG15 mrna Gane J. Hepatol. 63, (2015).
15 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).
16 NKT cell recognition of CD1d on infected hepatocytes. Baron. Immunity 16, (2002).
17 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).
18 Blocking MDSC-mediated suppression Pallett. Nat Med 21, (2015).
19 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).
20 Direct triggering of RIG-I in infected hepatocytes SB9200: Spring Bank Pharmaceutical RIG-I agonist Chronic Woodchuck Hepatitis Virus Infection model Korolowicz. PLoS ONE 11, e (2016).
21 Opportunities for Innate-targeted Immunotherapy A) Blocking NK TRAIL-mediated killing of HBV-specific T cells. B) Inducing presentation of the HBV antigen depot in monocytes C) TLR-8 activation of intrahepatic monocytes stimulating IL-12 and IL-18 D) TLR-7 mediated IFN-a production from plasmacytoid DC. E) NKT cell recognition of CD1d on infected hepatocytes. F) Blocking MDSC-mediated suppression G) Direct triggering of RIG-I in infected hepatocytes H) CpG induction of imates Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).
22 CpG induction of imates TLR-9 TNF-α Huang et. al. Nat Immunol Apr 14;14(6):
23 Opportunities for Innate-targeted Immunotherapy Multiple mechanisms that can potentially be exploited Maini & Gehring. J. Hepatol. 64, S60 S70 (2016).
24 Opportunities for Innate-targeted Immunotherapy Direct antiviral effect & potential environmental effect permit adaptive immunity Concern: Innate immunity is inherently non-specific Identify therapeutic window Effective intrahepatic immune response = inflammation Control/balance systemic toxicity Innate immunity is playing a significant regulatory role in chronic HBV What is regulating the regulators???? Understanding what is controlling the negative regulation by innate immunity may permit an organic immune response vs. therapeutic boosting.
Will Antigen Depletion Restore HBVspecific
Will Antigen Depletion Restore HBVspecific Immunity? Adam J. Gehring, Ph.D. Biology Lead Toronto Centre for Liver Disease University Health Network (UHN) Assistant Professor Department of Immunology University
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationHow does HBV interact with the immune system?
How does HBV interact with the immune system? International Workshop on HBV Cure Toronto 2017 Mala Maini Division of Infection and Immunity UCL Disclosures Mala Maini: collaborative research funding from
More informationCHRONIC HEPATITIS B VIRUS Prospects for Cure
VIRAL HEPATITIS and CO-INFECTION with HIV Bucharest, Romania, 6-7 October, 2016 CHRONIC HEPATITIS B VIRUS Prospects for Cure Patrick T. F. Kennedy Reader in Hepatology & Consultant Hepatologist Blizard
More informationAre Immune Modulators Really Needed to Cure HBV infection?
Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,
More informationCheckpoint inhibitors for HBV cure
Checkpoint inhibitors for HBV cure Mala Maini Division of Infection and Immunity UCL, London Toronto HBV Cure 2016 Reversal of T cell exhaustion: the goal of checkpoint inhibitors CD8 T cells Granzyme
More informationSupplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses.
Supplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses. Percentage of viable (A) pdcs (Sytox Blue-, Lin1-, HLADR+, BDCA2++)
More informationHBV Novel Therapies Maria Buti MD, PhD
HBV Novel Therapies Maria Buti MD, PhD Liver Unit, Internal Medicine Department Vall d Hebron Hospital CONFLICT OF INTEREST I have financial relationships to disclose within the past 12 months relevant
More informationMF Yuen 2, CS Coffin 3, M Elkhashab 4, S Greenbloom 5, A Ramji 6, H LY Chan 7, RP Iyer 1, S Locarnini 8, C Macfarlane 1, NH Afdhal 1, W Kim 9
SB 9200 (Inarigivir), an oral selective immunomodulator is safe and efficacious in treatment-naïve, non-cirrhotic HBV patients: Results from cohort 1 of the ACHIEVE Trial MF Yuen 2, CS Coffin 3, M Elkhashab
More informationReview New insights into how HBV manipulates the innate immune response to establish acute and persistent infection
Antiviral Therapy 2013; 18:1 15 (doi: 10.3851/IMP2542) Review New insights into how HBV manipulates the innate immune response to establish acute and persistent infection Peter Revill 1 *, Zhenghong Yuan
More informationImmunotherapy for Chronic Hepatitis B Virus Infection
Gut and Liver, Vol. 12, No. 5, September 2018, pp. 497-507 Review Immunotherapy for Chronic Hepatitis B Virus Infection Antonio Bertoletti 1,2 and Nina Le Bert 1,2 1 Emerging Infectious Diseases Program,
More informationTherapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees
Therapeutic Efficacy of a TLR7 Agonist for HBV Chronic Infection in Chimpanzees Robert Lanford 1, Bernadette Guerra 1, Deborah Chavez 1, Vida L. Hodara 1, Xubin Zheng 2, Grushenka Wolfgang 3, Daniel B.
More informationA preliminary report on the influence of baseline cellular immunity to the therapeutic responses of peg-interferon
146 2009 9 4 3 Journal of Microbes and Infection, September 2009, Vol. 4, No. 3 e 2a 1, 2, 1, 1, 1, 1, 1, 1 1., 200025; 2., 200032 : ( CHB) ( IFN), IFN IFN, e ( HBeAg) CHB 19, 14, IFN- 2a 180 g, 1, 48,
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationSB9200: A Novel and Efficacious RIG-I Agonist for Chronic Hepatitis B: Results from cohort 1 of the ACHIEVE Trial
SB9200: A Novel and Efficacious RIG-I Agonist for Chronic Hepatitis B: Results from cohort 1 of the ACHIEVE Trial Stephen Locarnini 2, Danny Wong 3, Kathy Jackson 2, Renae Walsh 2, Ros Edwards 2, Rachel
More informationNew insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
More informationCell-mediated Immunity
Cellular & Molecular Immunology Cell-mediated Immunity Nicholas M. Ponzio, Ph.D. Department of Pathology & Laboratory Medicine April 6, 2009 Today s Presentation: Overview Cellular Interactions In Humoral
More informationMechanisms of allergen-specific immunotherapy
2012 KAAACI/EAAS Spring Mechanisms of allergen-specific immunotherapy Woo-Jung Song, MD Division of Allergy and Clinical Immunology Department of Internal Medicine Seoul National University Hospital, Seoul,
More informationNew Drug Research for Chronic Hepatitis B Man-Fung Yuen, MD, PhD
New Drug Research for Chronic Hepatitis B Man-Fung Yuen, MD, PhD Department of Medicine. The University of Hong Kong, Queen Mary Hospital, Hong Kong OVERVIEW Emerging Drugs against HBV Direct-acting antiviral
More informationNovel Bispecific Antibodies for Treating Hepatitis B Virus Infection. Dr. Felix Bohne
Novel Bispecific Antibodies for Treating Hepatitis B Virus Infection Dr. Felix Bohne Munich, 11.05.2015 Consequences of Hepatitis B Virus 2 Global prevalence of Hepatitis B (percentage of population per
More informationAppendix 16. Open Session of the EuFMD: 2012, Jerez de la Frontera, Spain 1
The cellular innate immune response of cattle and swine to infection with foot-and-mouth disease virus (FMDV) Jared Patch, Pervaiz Dar, Ryan Waters, Mary Kenney, Raisa Glabman, Felix Toka and Bill Golde
More informationC. Ferrari Unit of Infectious Diseases and Hepatology Laboratory of Viral Immunopathology Azienda Ospedaliero-Universitaria di Parma Italy
HBV and the immune response C. Ferrari Unit of Infectious Diseases and Hepatology Laboratory of Viral Immunopathology Azienda Ospedaliero-Universitaria di Parma Italy List of topics - Kinetics of immune
More informationDendritic Cell Based Immunotherapy for Cancer. Edgar G. Engleman, M.D.
Dendritic Cell Based Immunotherapy for Cancer Edgar G. Engleman, M.D. Two main DC subsets Myeloid (mydc) Derived from monocytes Capture/process/present Ag to T cells Activate NK cells and B cells Plasmacytoid
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationImmunity to Viruses. Patricia Fitzgerald-Bocarsly September 25, 2008
Immunity to Viruses Patricia Fitzgerald-Bocarsly September 25, 2008 The Immune System Deals with a Huge Range of Pathogens Roitt, 2003 Immune Responses to Viruses Viruses are dependent on the host cell
More informationManipulating the Tumor Environment
Manipulating the Tumor Environment Vincenzo Bronte Verona University Hospital vincenzo.bronte@univr.it Escape from immune control can be viewed as one of the «Hallmarks of Cancer» D. Hanahan and R. A.
More informationHBV and the immune response
HBV and the immune response C. Ferrari Unit of Infectious Diseases and Hepatology Laboratory of Viral Immunopathology Azienda Ospedaliero-Universitaria di Parma Italy List of topics - Kinetics of immune
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationHepatitis B. HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, Lalo Flores, PhD Global Head HBV R&D
Hepatitis B HBV Cure: Insights for the Biotechnology and the Research Analyst Community November 11, 2016 Lalo Flores, PhD Global Head HBV R&D Infectious Diseases Diseases Infectious 11 Janssen s Vision
More informationThe Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease
Int. J. Mol. Sci. 2014, 15, 4747-4779; doi:10.3390/ijms15034747 Review OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms The Role of Chemokines in Hepatitis
More informationThe role of innate immunity in HBV infection
Semin Immunopathol (2013) 35:23 38 DOI 10.1007/s00281-012-0331-y REVIEW The role of innate immunity in HBV infection Qiuju Han & Cai Zhang & Jian Zhang & Zhigang Tian Received: 31 December 2011 /Accepted:
More informationSPONSOR & COPYRIGHT NOTICE
SPONSOR & COPYRIGHT NOTICE THIS PRESENTATION WAS GIVEN AT THE LIVER MEETING 2014 (AASLD), DURING AN INVESTIGATOR MEETING SPONSORED BY CN BIO INNOVATIONS LIMITED (UK REGISTERED COMPANY: 06517359) This presentation
More informationRegulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection
Gut Online First, published on September 12, 2017 as 10.1136/gutjnl-2017-314098 Hepatology Additional material is published online only. To view please visit the journal online (http:// dx. doi. org/ 10.
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationIMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, psoriasis
IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in mouse models of psoriasis Weiwen e Ja Jiang, Fu-Gang Zhu, Dong Yu, Ekambar R. Kandimalla, a a, Nicola La Monica, and Sudhir
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationAllergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.
Allergy and Immunology Review Corner: Chapter 13 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 13: Mechanisms of Immunity to Viral Disease Prepared by
More informationCytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression
Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression Jarad J Wilson, Ph.D. Technical Support & Marketing Specialist Ruo-Pan Huang, MD, Ph.D. Founder and CEO What are Antibody Arrays?
More informationHepatitis C Virus and Cytokine Responses
Hepatitis C Virus and Cytokine Responses Eui-Cheol Shin, M.D., Ph.D. Laboratory of Immunology & Infectious Diseases (LIID), Graduate School of Medical Science & Engineering (GSMSE), KAIST Daejeon, Korea
More informationCytokines (II) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:
Cytokines (II) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Learning Objectives By the end of this lecture you will be able to: 1 Understand the physiological
More informationAllergic rhinitis (Hay fever) Asthma Anaphylaxis Urticaria Atopic dermatitis
Hypersensitivity Disorders Hypersensitivity Disorders Immune Response IgE Disease Example Ragweed hay fever IgG Cytotoxic Immune complex T Cell Hemolytic anemia Serum sickness Poison ivy IgE-mediated Diseases
More informationImmunotherapy for HCC
Immunotherapy for HCC Jack R. Wands, MD Jeffrey and Kimberly Greenberg - Artemis and Martha Joukowsky, Professor in Gastroenterology and Professor of Medical Sciences, Director, Division of Gastroenterology
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationAntiangiogenesis - Immune Therapy Combinations. George Coukos, MD, PhD Heinz Zwierzina, MD
Antiangiogenesis - Immune Therapy Combinations George Coukos, MD, PhD Heinz Zwierzina, MD Overview Effect of VEGF on antitumor immune response Antigen presentation Effector mechanisms Ying and yang and
More informationInarigivir: A novel RIG-I agonist for chronic hepatitis B
: A novel RIG-I agonist for chronic hepatitis B Stephen Locarnini, Danny Wong, Kathy Jackson, Renae Walsh, Ros Edwards, Rachel Hammond, Carla S. Coffin, Magdy Elkhashab, Susan Greenbloom, Alnoor Ramji,
More informationHepatitis virus immunity. Mar 9, 2005 Rehermann and Nascimbeni review Crispe review
Hepatitis virus immunity Mar 9, 2005 Rehermann and Nascimbeni review Crispe review HBV & HCV infection outcomes Both viruses cause immune-mediated active and chronic hepatitis HBV Vertical transmission
More informationNewly Recognized Components of the Innate Immune System
Newly Recognized Components of the Innate Immune System NOD Proteins: Intracellular Peptidoglycan Sensors NOD-1 NOD-2 Nod Protein LRR; Ligand Recognition CARD RICK I-κB p50 p65 NF-κB Polymorphisms in Nod-2
More informationMeasles virus vaccine induces oncolysis of tumor cells and activates immune responses.
Measles virus vaccine induces oncolysis of tumor cells and activates immune responses. Marc Grégoire*, J.-F. Fonteneau, N. Boisgerault, J.-B. Guillerme and F. Tangy. * INSERM, Nantes, F-44, France. Pasteur
More informationInduction of Innate Immune Responses in HVTN 071: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study
Induction of Innate Immune Responses in HVTN 71: a Trial using the MRKAd5 gag/pol/nef Vaccine from the Step Study Erica Andersen-Nissen Vaccine and Infectious Disease Institute Fred Hutchinson Cancer Research
More informationThe gut kidney axis in IgA nephropathy. Rosanna Coppo. Fondazione Ricerca Molinette Torino
The gut kidney axis in IgA nephropathy Rosanna Coppo Turin, Italy Fondazione Ricerca Molinette Torino IgA nephropathy (IgAN): a disease originated from mucosal immunity dysregulation IgA: most prevalent
More informationSlides are the property of the author and AASLD. Permission is required from both AASLD and the author for reuse.
Inarigivir Demonstrates Potent Dose Dependent Anti-Viral Activity in HBV Treatment-Naïve Patients: Role of HBeAg Status and Baseline HBsAg in Anti-Viral Response MF Yuen, M. Elkhashab, CY Chen, YF Chen,
More informationEffects of Inarigivir (SB9200) Therapy on Immune Responses in Patients with Chronic Hepatitis B (CHB)
Effects of (SB9200) Therapy on Immune Responses Patients with Chronic Hepatitis B (CHB) Renae Walsh 1, Rachel Hammond 1, Kathy Jackson 1, Ros Edwards 1, Chelsea Macfarlane 2, Radhakrishnan P. Iyer 2, Man
More informationInnate Immunity and Inflammation
SITC Primer on Tumor Immunology and Biological Therapy of Cancer Innate Immunity and Inflammation Willem Overwijk, Ph.D. MD Anderson Cancer Center Center for Cancer Immunology Research Houston, TX www.allthingsbeautiful.com
More informationInnate Immunity: (I) Molecules & (II) Cells
Innate Immunity: (I) Molecules & (II) Cells Stephanie Eisenbarth, M.D., Ph.D. FOCIS Advanced Course 2/19/18 Department of Laboratory Medicine Yale School of Medicine Department of Immunobiology Yale School
More informationHBV Cure Overview of Viral and Immune Targets
HBV Cure Overview of Viral and Immune Targets Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto, Canada October
More informationCYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION
CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION What is Cytokine? Secreted popypeptide (protein) involved in cell-to-cell signaling. Acts in paracrine or autocrine fashion through specific cellular receptors.
More informationImmunobiology of hepatitis B virus infection
bs_bs_banner doi: 10.1111/hepr.12439 Review Article Immunobiology of hepatitis B virus infection Masanori Isogawa and Yasuhito Tanaka Department of Virology and Liver Unit, Nagoya City University Graduate
More informationOverview of Immunology. Evolution CORE CONCEPTS IN IMMUNOLOGY. Cliona O Farrelly
Overview of Immunology Cliona O Farrelly Professor Comparative Immunology, School of Biochemistry & Immunology & School of Health Sciences cliona.ofarrelly@tcd.ie CORE CONCEPTS IN IMMUNOLOGY 1. Identification
More informationHepatitis B New Therapies
Hepatitis B New Therapies Richard K. Sterling, MD, MSc, FACP, FACG, FAASLD, AGAF VCU Hepatology Professor of Medicine Chief, Section of Hepatology Fellowship Director, Transplant Hepatology Virginia Commonwealth
More informationInnate Immunity, Inflammation and Cancer
Innate Immunity, Inflammation and Cancer Willem Overwijk, Ph.D. Melanoma Medical Oncology Center for Cancer Immunology Research MD Anderson Cancer Center, Houston, TX SITC/MDACC -6/14/2013 www.allthingsbeautiful.com
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationCD40L TCR IL-12 TLR-L
CD40L B cells plasmacells Neutrophils TCR inkt cells IL-12 Ab production Can inkt cells modulate the cytokine profile of neutrophils? TLR-L CD4+ and CD8+ T cell responses 1. The invariant TCR expressed
More informationTherapeutic immunization strategies in chronic hepatitis B
Therapeutic immunization strategies in chronic hepatitis B Mengji Lu Institut für Virologie Universitätsklinkum Essen Falk Symposium Berlin, 04. October 2005 The aim of therapeutic immunization to achieve
More informationEffector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells
ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction
More informationCan HPV, cervical neoplasia or. HIV transmission?
Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV Jennifer S. Smith Department of Epidemiology pd University of North Carolina Can HPV, cervical
More informationNTD Vaccine Design Toolkit and Training Workshop Providence, RI January 05, 2011 Cytokines Leslie P. Cousens, PhD EpiVax, Inc.
NTD Vaccine Design Toolkit and Training Workshop Providence, RI January 05, 2011 Cytokines Leslie P. Cousens, PhD EpiVax, Inc. Cytokines Properties of Cytokines Cytokines are proteins with specific roles
More informationIsorce Nathalie, Testoni B., Luangsay S., Locatelli M., Zannetti C., Henry T., Hasan U., Zoulim F., Durantel D.
Activité antivirale de différents interférons (IFNs) et cytokines proinflammatoires dans des modèles pertinents d hépatocytes infectés par le virus de l hépatite B (HBV) Isorce Nathalie, Testoni B., Luangsay
More informationSystem Biology analysis of innate and adaptive immune responses during HIV infection
System Biology analysis of innate and adaptive immune responses during HIV infection Model of T cell memory persistence and exhaustion Naive Ag+APC Effector TEM (Pfp, Gr.B, FasL, TNF) Ag stim. IL-2, IL-7,
More informationNew Interferons and Immunomodulators
New Interferons and Immunomodulators T. Jake Liang, M.D. Bethesda, MD, USA Interferons What are they? Who cares? The Interferon family Type 1: 3 subtypes, all cell types, IFNAR1 and 2 IFN-α, 14 species
More information1. TLR. TLR Toll-like receptors. Toll Toll-like receptor, TLR TLR TLR TLR. type I TLR TLR. Toll
54pp.145 152 2004 1. TLR T B TLR Toll-like receptors TLR TLR I IFN TLR T B B T Toll NF- B 1996 565-0871 3-1 TEL 06-6879-8303 FAX 06-6879-8305 E-mail uemattsu@biken.osaka-u.ac.jp Toll Toll-like receptor,
More informationInnate Immunity & Inflammation
Innate Immunity & Inflammation The innate immune system is an evolutionally conserved mechanism that provides an early and effective response against invading microbial pathogens. It relies on a limited
More informationInnate and adaptive immunity have evolved
Immune Response in Hepatitis B Virus Infection Anthony Tan 1, Sarene Koh 2, and Antonio Bertoletti 1,2,3 1 Program Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore 169857 2 Viral
More informationAutoimmune Diseases. Betsy Kirchner CNP The Cleveland Clinic
Autoimmune Diseases Betsy Kirchner CNP The Cleveland Clinic Disclosures (financial) No relevant disclosures Learning Objectives Explain the pathophysiology of autoimmune disease Discuss safe administration
More informationHCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud
HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud Service d Hépatologie et INSERM UMR1149, AP-HP Hôpital Beaujon, Paris, France. emilie.estrabaud@inserm.fr
More informationin vitro in vivo [hemagglutinating virus of Japan envelope (HVJ-E)] HVJ-E (Scid) HVJ-E HVJ-E
57 pp.19-282007 1. [hemagglutinating virus of Japan envelope (HVJ-E)] HVJ-E HVJ-E 60% 80% (Scid) In vitro HVJ-E HVJ(live HVJ) HVJ-E live HVJ IL-6 RT-PCR HVJ-E CD4 + T CD8 + T T (CTL) HVJ-E Foxp3 + CD4
More informationAllergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.
Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared
More informationImmunology. T-Lymphocytes. 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters,
Immunology T-Lymphocytes 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters, karin.peters@rub.de The role of T-effector cells in the immune response against microbes cellular immunity humoral immunity
More informationImmunotherapy in Lung Cancer - TLR9 as a therapeutic target -
Immunotherapy in Lung Cancer - TLR9 as a therapeutic target - Wilfried Eberhardt,, MD Head of Outpatient Unit, Dept. of Internal Medicine (Cancer Research) West German Cancer Centre Essen University Hospital
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationIntracellular MHC class II molecules promote TLR-triggered innate. immune responses by maintaining Btk activation
Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining Btk activation Xingguang Liu, Zhenzhen Zhan, Dong Li, Li Xu, Feng Ma, Peng Zhang, Hangping Yao and Xuetao
More informationShiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School
CTLs, Natural Killers and NKTs 1 Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School CTL inducing tumor apoptosis 3 Lecture outline CD8 + Cytotoxic T lymphocytes (CTL) Activation/differentiation
More informationImmunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine
Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline Consensus characteristics/incidence data Immune/inflammatory basis Etiology/Genetic basis Hygiene
More informationIntrinsic cellular defenses against virus infection
Intrinsic cellular defenses against virus infection Detection of virus infection Host cell response to virus infection Interferons: structure and synthesis Induction of antiviral activity Viral defenses
More informationApoptosis in chronic hepatitis C
Apoptosis in chronic hepatitis C Dr med. Anna Parfieniuk-Kowerda Department of Infectious Diseases and Hepatology Medical University of Bialystok Poland APOPTOSIS Apoptosis - type I programmed cell death
More informationInnate immunity. Abul K. Abbas University of California San Francisco. FOCiS
1 Innate immunity Abul K. Abbas University of California San Francisco FOCiS 2 Lecture outline Components of innate immunity Recognition of microbes and dead cells Toll Like Receptors NOD Like Receptors/Inflammasome
More informationInnate Immunity and the Paradoxes of Viral Pathogens and Tissue Injury in Gene Therapy
Innate Immunity and the Paradoxes of Viral Pathogens and Tissue Injury in Gene Therapy Daniel R. Salomon, M.D. Department of Molecular and Experimental Medicine The Scripps Research Institute Tissue and
More informationAccepted Manuscript. Innate immune cells regulate oncoimmunity and cancer development. Ai-Ping Bai, Yuan Guo
Accepted Manuscript Innate immune cells regulate oncoimmunity and cancer development Ai-Ping Bai, Yuan Guo PII: S0016-5085(18)34974-6 DOI: 10.1053/j.gastro.2018.08.057 Reference: YGAST 62119 To appear
More informationLa risposta immune all infezione da virus ebola. Chiara Agrati, PhD
La risposta immune all infezione da virus ebola Chiara Agrati, PhD Pathogenetic mechanisms This virus infection is able to: - disable the immune system, preventing an effective protective immune response
More information核酸アジュバントによる 樹状細胞活性化の分子メカニズム
ワクチンフォーラム 2010 September 14, 2010 核酸アジュバントによる 樹状細胞活性化の分子メカニズム 理研 免疫 アレルギー科学総合研究センター生体防御研究チーム改正恒康 Homepage:http://www.riken.jp/hosdef/ index.html Nucleic acid-sensing receptors Virus Plasma membrane Endosome
More informationInves)gación básica y curación del VIH- 1
Inves)gación básica y curación del VIH- 1 Javier Mar)nez- Picado (jmpicado@irsicaixa.es) 23 rd Conference on Retroviruses and Opportunis5c Infec5ons February 22-25, 2016 Boston, Massachuse8s UNIVERSITAT
More informationThe g c Family of Cytokines Prof. Warren J. Leonard M.D.
The Family of Cytokines Chief, Laboratory of Molecular Immunology Director, Immunology Center National Heart, Lung, and Blood Institute National Institutes of Health Department of Health and Human Services
More informationTherapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells
Therapeutic Immunization with Autologous DC Pulsed with Autologous Inactivated HIV-1 Infected Apoptotic Cells Sharon A. Riddler, MD, MPH University of Pittsburgh May 2008 Slide 1 HIV and DC Vaccines During
More informationImmunology lecture: 14. Cytokines: Main source: Fibroblast, but actually it can be produced by other types of cells
Immunology lecture: 14 Cytokines: 1)Interferons"IFN" : 2 types Type 1 : IFN-Alpha : Main source: Macrophages IFN-Beta: Main source: Fibroblast, but actually it can be produced by other types of cells **There
More informationRationale for Combining Immunotherapy with Chemotherapy or Targeted Therapy
Society for Immunotherapy of Cancer (SITC) Rationale for Combining Immunotherapy with Chemotherapy or Targeted Therapy Qing Yi, MD, PhD Staff and Chair, Department of Cancer Biology Betsy B. DeWindt Endowed
More informationFrequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection
1 Evolution, Medicine, and Public Health [2014] pp. 1 9 doi:10.1093/emph/eot023 commentary Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection Brook G. Warner
More informationThe Use of Human Dendritic Cell
The Use of Human Dendritic Cell Subsets in Cancer Vaccines Jolien Sweere Student #: 3145298 Master Thesis Infection and Immunity Supervisor: Dr. Jeanette Leusen Immunotherapy University Medical Centre
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationHost virus interactions in hepatitis B and hepatitis C infection
J Gastroenterol (2016) 51:409 420 DOI 10.1007/s00535-016-1183-3 REVIEW Host virus interactions in hepatitis B and hepatitis C infection Sachiyo Yoshio 1 Tatsuya Kanto 1 Received: 24 December 2015 / Accepted:
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More information